- Record Q4 Revenue: Achieved $62.1 million, an 8% YoY increase and the highest quarterly revenue in company history.
- Recurring Revenue Growth: Represented 34% of total revenue in 2025, growing 21% YoY.
- Regional Performance: APAC revenue rose 15% YoY, driven by instrument, service, and reagent growth; EMEA and U.S. saw stabilization and double-digit service revenue growth.
- Margin Pressure: Adjusted gross margin fell to 55% in Q4 2025 from 61% in Q4 2024, with operating expenses up 25% YoY to $38.5 million.
- 2026 Outlook: Revenue guidance set at $205–212 million, reflecting improved U.S./EMEA markets and sustained APAC growth.
Geographic Performance
The company's geographic performance was mixed, with EMEA and APAC posting double-digit year-over-year revenue increases in Q4, while the U.S. grew 5%. APAC revenue grew 15% in Q4, driven by growth in instrument, service, and reagent revenue. According to Wenbin Jiang, "revenue growth was driven by stabilization and growth in the U.S., a turnaround in the EU, continued strength in APAC, and solid expansion of recurring revenue businesses worldwide."
Recurring Revenue and Software Ecosystem
Cytek's recurring revenue continued to strengthen, representing 34% of total revenue in 2025 and growing 21% year-over-year. The company's software ecosystem, including the Cytek Cloud, is a powerful growth driver, with over 24,000 users by year-end 2025. This is a significant development, as it indicates a growing and loyal customer base.
Operating Expenses and Cash Position
Total operating expenses were $38.5 million, up $7.8 million or 25% versus Q4 2024. Loss from operations was $5.6 million for Q4. The company's cash and marketable securities decreased to $261.5 million at December 31, 2025, from $261.7 million at the end of the third quarter.
Outlook and Valuation
For 2026, the company initiated a revenue outlook of $205 million to $212 million, assuming constant currency exchange rates. Analysts estimate next year's revenue growth at 8.3%. With a P/S Ratio of 2.84 and an EV/EBITDA of -31.11, the market is pricing in significant growth expectations. The current valuation metrics indicate that the market has high expectations for the company's future performance.
Conclusion on Financial Health
The company's financial health is a concern, with a Net Debt / EBITDA of 4.82 and a ROE of -18.01%. The adjusted EBITDA was $5 million in 2025, a decline of $17.4 million from $22.4 million in 2024. The company's commitment to improving these metrics going forward will be crucial in restoring investor confidence.